Kornimate/medical-research-clean huggingface dataset:
comparing two different cervical collars for the treatment in patient with cervical radiculopathy and radicular pain

Conditions: Cervical Radiculopathy; Radicular Pain; Acute Neck Pain; Cervicobrachial Pain

Summary: the primary objective of the study is to investigate the efficacy of device with far-infrared (fir) irradiation in these patients with acute cervical radiculopathy.

acute neck pain is a relatively common experience that usually declines and disappears within a couple weeks. some patients do not recover and with time develop chronic cervical pain and nerve root compression which may result in cervical radiculopathy. far-infrared (fir) ray is one of the topics in energy medicine which is tremendously studied for the past few years. a variety of fir applications showed an enhancement of beneficial effects on healing therapy, even though there is limited technical approach and systemic study placed on the theoretical study of fir ceramics processing and the emissivity optimizing. the evident difficulties in finding the appropriate cervical radiculopathy therapy initiated the current study. the aim of the study is to evaluate the efficacy of the fir cervical collar in patients with long-lasting cervicobrachial pain; in whom the pain had a distribution that corresponded to a specific nerve root compression revealed by mri or electrophysiological study.

Eligibility criteria:
inclusion criteria: * age greater than 20 years * cervical radiculopathy defined by neck pain irradiating to one arm with at least one of the following: 1. provocation by neck movements or sensory changes in one or more adjacent dermatomes or diminished deep tendon reflexes in the affected arm. 2. muscle weakness in one or more adjacent myotomes. * neck disability index (ndi) score greater than or equal to 10 points * visual analog scale (vas) score for neck pain greater than or equal to 40mm * c-spine x-ray signs judge by investigator * prolong neck pain for one week or longer * written consent from patient exclusion criteria: * serious somatic or psychiatric disease(s) * history of spinal tumors or spinal infection * ongoing physical therapy within 4 weeks * cervical instability judge by investigator * history of contact dermatitis or known allergic reaction to collar material * known allergic reaction to acetaminophen * any other clinical condition which, in the opinion of the principal investigator, would not allow completion of this study

Keywords: cervical radiculopathy radicular pain acute neck pain cervicobrachial pain far-infrared ray fir cervical collar cervical device fir device
thrombosis and neurocognition in klinefelter syndrome

Conditions: Klinefelter Syndrome; Thrombosis

Summary: the haemostatic balance and neurocognitive capability of men with klinefelter syndrome is compared to healthy controls by using specific biochemical assays for coagulation and fibrinolysis and a selection of neuropsychological tests and brain fmri. furthermore, the effect of gonadal status and any effects of long- or short-term testosterone treatment on the above mentioned parameters are investigated.

klinefelter syndrome (ks) affects approximately 1 in every 600 males, but remains severely underdiagnosed. men with ks are more prone to a wide range of diseases including thrombotic disorders. also, neurocognitive function is impaired in ks. the background for the increased thrombosis proneness is not understood, and also it is not understood how testosterone treatment affects the thrombosis risk in ks. the effects of testosterone treatment on neurocognition in ks is also not completely understood. however, it is speculated that testosterone treatment at an early point could help improve the overall neurocognitive performance. in this study 30 males with ks receiving testosterone treatment, 30 males with ks not receiving testosterone treatment and 60 matched healthy male controls are included. after initial examination including blood testing and neurocognitive testing, the subjects are followed for 18 months and examined a second time. after initial examination the group of previously untreated ks males will be put on standard testosterone treatment according to current guidelines. groups will be compared by measuring and array of markers for coagulation and fibrinolysis, including thrombin generation and fibrin structure analysis, to assess the haemostatic balance. also, a wide array of neurocognitive tests and brain fmri is applied to compare the neurocognitive function between the groups.

Eligibility criteria:
inclusion criteria: * klinefelter syndrome with 47 xxy karyotype * healthy male exclusion criteria: * known thrombophilia * previous thrombotic event * chronic or acute illness affecting the haemostatic balance (e.g. diabetes, cancer). * previous or current disease affecting the brain * weight above 120 kg * current abuse of stimulants affecting the brain * unability to complete mr-scan (e.g. claustrophobia, internal metal objects)

Keywords: testosterone neurocognition
a study of ibi362 in chinese subjects with obstructive sleep apnea and bmi≥28 kg/m2

Conditions: Sleep Apnea; Obstructive; Obesity

Summary: this is a multicenter, randomized, double-blind, placebo-controlled phase iii clinical study to evaluate the efficacy and safety of ibi362 in subjects with moderate-to-severe obstructive sleep apnea (osa) and a body mass index (bmi) ≥28 kg/m2. subjects will be randomly assigned to ibi362 9 mg and placebo groups. all study treatment will be administered once-weekly and subcutaneously. the entire trial cycle includes a 4-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.


Eligibility criteria:
inclusion criteria: * for pap s: subjects who have received positive airway pressure (pap) therapy for at least 3 consecutive months prior to screening and plan to continue pap therapy during the study. * for non-pap s:subjects who are unable or unwilling to undergo pap therapy. pap must not have been used for at least 4 weeks prior to screening. * for all subjects: 1. age ≥18 years at the time of signing informed consent. 2. polysomnography (psg) during screening shows an apnea-hypopnea index (ahi) ≥15 events/hour. 3. body mass index (bmi) ≥28.0 kg/m² at screening. exclusion criteria: for paps： * have personal or job-related responsibilities, or in the opinion of the investigator have any situation, that would make it unsafe to stop pap therapy for 7 days prior to psg testing during the course of the study * are unwilling to stop pap therapy for 7 days prior to polysomnography (psg) testing during the course of the study for all subjects： * have type 1 diabetes mellitus (t1dm) or type 2 diabetes mellitus (t2dm). * any previous or planned surgery for sleep apnea or major ear, nose or throat surgery, including tonsillectomy and adenoidectomy that still may affect breathing at time of baseline * have significant craniofacial abnormalities that may affect breathing at baseline * diagnosis of obesity hypoventilation syndrome or daytime hypercapnia. * active device treatment of osa other than pap therapy (for example, dental appliance), or other treatment, that in the opinion of the investigator, may interfere with study outcomes, unless willing to stop treatment at baseline and throughout the study. * respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator. * have achieved a \>5% change in body weight through diet and exercise alone for at least 12 weeks prior to screening.
safety and tolerability study of mdv3100 in combination with docetaxel in men with advanced prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine the safety of mdv3100 given in combination with docetaxel in men with advanced prostate cancer.


Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent; * men, 18 years of age or older; * histologically or cytologically confirmed adenocarcinoma of the prostate; * ongoing androgen deprivation therapy exclusion criteria: * severe concurrent disease; * known or suspected brain metastasis; * history of another malignancy within the previous 5 years; * prior treatment with docetaxel-based chemotherapy

Keywords: prostate cancer docetaxel mdv3100 enzalutamide xtandi
same-day antiretroviral therapy initiation

Conditions: HIV Infections

Summary: data from a total of 2,500 walk-in or referred individuals who have been confirmed (diagnosed) hiv positive and accessing care and treatment services at the hospitals targeted by this study will be examined. the starting period for this project is estimated to be the last quarter (q4) of fiscal year 2018.

this 24-month observation study will be conducted in 13 hospitals of 5 provinces in thailand: chiang rai, chiang mai, ubon ratchathani, chonburi, and songkhla. the research team of trcarc will collect and analyze secondary and de-identified data from the hospitals' databases. in each site, clients who agree to receive same-day art service will go through standard of care procedures at each hospital, which include: post-test counseling and psychosocial support, baseline lab test, clinical screening, and physical examination. the drug regimen prescribed for clients will mirror the first line art regimen in thailand's national guideline, which is tenofovir (tdf), emtricitabine (ftc), and efavirenz (efv). retention of the clients will reflect that of the hospital's protocol, and cd4 and viral load will be tested according to the national guideline.

Eligibility criteria:
inclusion criteria: 1. thai nationals 2. hiv-positive status 3. acceptance of same-day art exclusion criteria: 1. not acceptance of same-day art
influence of analgesia and neuromuscular block on abdominal distension and operating conditions laparoscopic operations

Conditions: Neuromuscular Blockade

Summary: neuromuscular block improves operation conditions during laparoscopic surgery. in this study, a new measurement tool is assessed: the degree of abdominal distension during the time course of the neuromuscular block is measured and compared with a standardized score (surgical rating score).


Eligibility criteria:
inclusion criteria: * laparoscopic gynecologic surgery * american society of anesthesiologists physical status asa 1-2 exclusion criteria: * anticipated difficult airway * increased risk for pulmonary aspiration * acute infection * pregnancy * impaired liver- oder kidney function * neuromuscular disease * chronic intake of drugs known to influence neuromuscular blockade
intraoperative s-ketamine to prevent postoperative hyperalgesia in patients undergoing video-assisted thoracic surgery

Conditions: Postoperative Hyperalgesia

Summary: postoperative hyperalgesia (poh) is a paradoxical clinical state of increased sensation of pain or increased sensitivity to non-painful stimuli at the site of surgery or at a surrounding area that was not directly injured. opioid-induced hyperalgesia (oih) and nociceptive-induced hyperalgesia (nih) are the two main causes of poh.n-methyl-d-aspartate receptor (nmdar) activation plays a central role in the development of poh.s-ketamine，which is a nmda-receptor antagonist,has been on the market in china since 2019.the aim of this study is to evaluate the effects of s-ketamine on poh and chronic postoperative pain after video-assisted thoracic surgery.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status class i-iii. * elective single-port video-assisted thoracic surgery under general exclusion criteria: * a history of thoracic surgery * a history of chronic pain * ongoing pain treatment * opioid drug or alcohol abuse * a history of allergy to anesthetics * obesity (body mass index \[bmi\] \>30 kg/m2 ) * pregnancy * psychiatric disorders * neurological disease * severe diabetes * renal or hepatic insufficiency * uncontrolled hypertension, or arrhythmia
a study of ly3819253 (ly-cov555) in participants hospitalized for covid-19

Conditions: COVID-19

Summary: the purpose of this study is to test the safety and tolerability of ly3819253 when it is given by injection into a vein to participants hospitalized with covid-19. blood tests will be done to check how much ly3819253 is in the bloodstream and how long the body takes to eliminate it. participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.


Eligibility criteria:
inclusion criteria: * are hospitalized or in the process of being admitted to hospital and have an initial laboratory determination of current covid-19 infection less than or equal to (≤)72 hours prior to randomization * are men or non-pregnant women * women of childbearing potential must agree to use at least one highly effective form of contraception for the entirety of the study * agree to the collection of nasopharyngeal swabs and venous blood exclusion criteria: * require mechanical ventilation or anticipated impending need for mechanical ventilation * received convalescent covid-19 plasma treatment prior to enrollment * were resident in a nursing home or long-term care facility immediately prior to current hospitalization * suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking investigational product * have an oxygen saturation (spo2) less than (\<)88 percent (%) while breathing room air at rest at randomization.
confronting cancer as a community

Conditions: Colorectal Carcinoma

Summary: this study aims to better understand the cause of colorectal cancer and how to find the best treatment for hispanic patients with colorectal cancer. the genetic information in the blood and tissues may explain why patients who have the same type of cancer and receive the same treatment do not always have the same results. by combining genetic (certain qualities or traits passed from parents to offspring) information with clinical data, such as the responses of different kinds of cancers to different treatments, this study could lead to more knowledge about why certain cancers occur and why they respond differently to treatments. information gathered from this study may help researchers match treatments to the genetics of each patient and the genetic changes in their tumor. this approach is known as personalized medicine.

primary objective: i. to create a well-characterized cohort of hispanic patients with colon cancer, with patient-level data, genomic, transcriptomic, clinical, and outcomes data. secondary objectives: i. to identify genomic/transcriptomic predictors of treatment outcomes (time to recurrence, time to progression, and overall survival). ii. to identify associations between somatic tumor deoxyribonucleic acid (dna) methylation patterns and clinical outcomes. iii. to examine patterns of patient engagement in genetic/genomic testing among hispanic patients with colorectal cancer (crc). iv. to characterize the gut microbiome through a stool collection kit and nucleic acid extraction process. exploratory objectives: i. to validate, characterize and discover molecular processes in the crc tumor common to other crc populations and specific to hispanic patients. ii. to determine whether comorbidities are associated with variation in tumor molecular pathways and whether comorbidities are effect modifiers of associations between tumor molecular variation and disease outcomes and response to treatment in hispanic crc patients. outline: this is an observational study. patients undergo blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. patients also have their medical records reviewed on study. after return of genetic testing results, patients are followed up at 2 weeks, 12 months, and then annually thereafter.

Eligibility criteria:
inclusion criteria: * self-reported hispanic ethnicity * diagnosed with colon or rectal cancer (at any time and stage; lifetime diagnosis and in survival are eligible) * has a tumor tissue sample archived or plans to have tissue archived from a standard care procedure * age \>= 18 years exclusion criteria: * inability to understand and the willingness to sign a written informed consent
patient-derived xenograft (pdx) modeling to test drug response for high-grade osteosarcoma

Conditions: Osteosarcoma

Summary: by obtaining clinical specimens from participants with high-grade bone and soft tissue sarcomas to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with individualized cancer treatment options

patient-derived xenografts (pdx) are increasingly used as tools for drug development in pre-clinical settings, and have been shown to recapitulate the histology and behavior of the cancers from which they are derived. although, they have been commonly used productively as pre-clinical disease models to study disease biology and drug response, they have not been used prospectively to inform clinical management. pdx have been employed to inform clinical decision-making in small studies, which have shown high concordance between individual pdx and patient responses to therapy. while encouraging, the role of this approach in bone and soft tissue sarcomas and in the context of genomic drug matching strategies remains undefined. this has created an opportunity to evaluate the utility of pdx as clinical predictors to direct the use of chemo- and targeted therapies in combination with comprehensive genomic and epigenetic analysis for patients with bone and soft tissue sarcomas.

Eligibility criteria:
inclusion criteria: 1. age \>18 years; 2. diagnosis confirmed histologically and reviewed centrally; 3. prior treatment (completed \>4 weeks before trial entry) consisted of standard high-grade osteosarcoma chemotherapy agents including doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide; metastatic relapsed and unresectable progressive disease (pd); 4. eastern cooperative oncology group performance status 0-1 with a life expectancy \>3 months; 5. adequate renal, hepatic, and hemopoietic function; 6. normal or controlled blood pressure; 7. surgery and/or radiotherapy completion at least 1 month before enrollment. exclusion criteria: 1. central nervous system metastasis; 2. have had other kinds of malignant tumors at the same time; 3. cardiac insufficiency or arrhythmia; 4. uncontrolled complications, such as diabetes mellitus and so on; 5. coagulation disorders; 6. urine protein≥ ++; 7. pleural or peritoneal effusion that needs to be handled by surgical treatment; 8. combined with other infections or wounds.

Keywords: osteosarcoma patient-derived xenograft
liraglutide and cardio-metabolic risk markers

Conditions: Type-2 Diabetes

Summary: incretin-based therapies have shown significant effects beyond those on glucose metabolism. we aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.

in details, we will evaluate the effects of liraglutide on carotid-intima media thickness, oxidative stress, ghrelin, heat shock proteins and lipoproteins.

Eligibility criteria:
inclusion criteria: - patients with a diagnosis of type-2 diabetes exclusion criteria: - severe hepatic or renal diseases

Keywords: diabetes, cardiovascular risk
safety, tolerability, and immunogenicity study of a cell-based virosomal influenza vaccine in healthy adults

Conditions: Influenza

Summary: the purpose of this study is to examine the safety and tolerability after administration of trivalent and quadrivalent cell-based virosomal influenza vaccine in healthy adults.

this is a double-blind and randomized study in healthy adults. the duration of study will be approximately 90 days per participant. the study will include 4 visits: day 1 (for vaccination), day 4, day 22 and day 90 (follow-up visits). safety and tolerability will be assessed by the rate of solicited, unsolicited, and serious adverse events.

Eligibility criteria:
inclusion criteria: * healthy male or female adults * body mass index \<= 30 kilogram per square meter (kg/m\^2) * written informed consent exclusion criteria: * vaccination with 2013/2014-seasonal influenza vaccine and/or receipt of any vaccine in the 4 weeks preceding receipt of study vaccine and/or any vaccination planned within 3 weeks from the study vaccine * diagnosis (by rapid test, performed at clinic/hospital laboratory) of laboratory-confirmed influenza in the 2013/2014 season * acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease * acute febrile illness (greater than or equal to 38.0 celcius) * pregnancy as assessed by urine pregnancy test before vaccination, or lactation. women of childbearing potential (that is, not surgically sterilized/hysterectomized or post-menopausal for more than 2 years) will be excluded if one of the following criteria is met: 1). intention to become pregnant during the course of the study or to donate eggs (ova, oocytes) for the purposes of assisted reproduction 2). if heterosexually active, not using or not willing to continue using a medically reliable method of contraception for the entire study duration (up to 90 days). a medically reliable method of contraception includes oral contraceptive preparation (for example pills), hormonal implant, progestative injection, patch contraceptive formulation, an intrauterine device, concomitant use of barrier method and spermicide, or another method considered sufficiently reliable by the investigator in individual cases

Keywords: healthy participants immunogenicity influenza prevention safety
pituitary carcinoma or aggressive tumors registry -lyon

Conditions: Pituitary Tumor

Summary: the purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.


Eligibility criteria:
inclusion criteria: • patients with confirmed pituitary disease exclusion criteria: • patients who do not have confirmed pituitary disease

Keywords: pituitary tumor pituitary carcinoma acromegaly cushing prolactinoma
postoperative nausea and vomiting: to estimate the incidence and risk factors in a tertiary teaching hospital

Conditions: Postoperative Nausea and Vomiting

Summary: postoperative nausea and vomiting (ponv) is a frequent complication of surgery and anesthesia. the aim of this study is to estimate the incidence and the risk factors of ponv at jordan university hospital over one year period.

postoperative nausea and vomiting (ponv) is a frequent complication of surgery and anesthesia, in the literature it reaches up to 70% of the surgical patients and it occurs after local and general anesthesia with surgery. locally in jordan there was no proper clinical study to estimate ponv among surgical patients, the aim of this study is to estimate the incidence and the risk factors of ponv at jordan university hospital over one year period.

Eligibility criteria:
inclusion criteria: * patients who undergoes anesthesia and surgery. * patients who suffer from postoperative nausea and vomiting for 24 hours. exclusion criteria: * patients who suffer from postoperative nausea and vomiting after 24 hours. * patients who undergoes day-case surgery.

Keywords: anesthesia postoperative nausea vomiting